Denali Therapeutics (DNLI) Non Operating Income (2017 - 2023)

Denali Therapeutics (DNLI) has 7 years of Non Operating Income data on file, last reported at $13.1 million in Q4 2023.

• Quarterly Non Operating Income rose 97.13% year-over-year to $13.1 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $51.5 million (up 248.62% YoY) and the FY2023 annual result came in at $51.5 million, up 248.62% from the prior year.
• Non Operating Income retreated to $13.1 million in Q4 2023 per DNLI's latest filing, from $14.4 million in the prior quarter.
• Across five years, Non Operating Income topped out at $14.4 million in Q3 2023 and bottomed at $1.0 million in Q3 2021.
• The 5-year median for Non Operating Income is $3.1 million (2020), against an average of $4.8 million.
• The widest annual swing landed in 2021, when Non Operating Income plunged 61.58%; it then surged 763.38% in 2023.
• Tracing DNLI's Non Operating Income over 5 years: stood at $3.8 million in 2019, then plunged by 56.9% to $1.6 million in 2020, then dropped by 21.17% to $1.3 million in 2021, then jumped by 418.29% to $6.7 million in 2022, then jumped by 97.13% to $13.1 million in 2023.
• Per Business Quant, the three latest DNLI Non Operating Income figures stand at $13.1 million (Q4 2023), $14.4 million (Q3 2023), and $12.9 million (Q2 2023).

Peer Comparison